This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, debuts the versatile on-body drug delivery platform Vertiva™ at the PDA Universe and the CPhI Barcelona in autumn.
Vertiva™ platform is the latest addition to Stevanato Group’s comprehensive portfolio of products and devices for drug delivery. After the official announcement last summer, the live presentation of Vertiva™ at the PDA Universe (Gothenburg, Sweden, Oct. 17-18) and CPhI (Barcelona, Spain, Oct. 24-26) is an opportunity for Stevanato Group to showcase its commitment to advancing drug delivery technology in empowering pharmaceutical companies to bring innovative therapies to patients around the world.
At the PDA Universe of Pre-filled Syringes and Injection Devices Conference attendees visiting Stevanato Group’s booth 69 had the exclusive opportunity to witness firsthand the capabilities and potential of Vertiva™ platform for drug delivery and EZ-fill Smart™ ready-to-use vial platform for aseptic manufacturing.
During the conference, Stevanato Group’s team jointly shared insights with Bayer’s and Thermo Fischer Scientific’s experts to show how they are driving together transformative innovation to enhance contract manufacturing services and drug delivery devices portfolio to support biopharma companies.
Stevanato Group will be showcasing its complete portfolio of products, technologies, and innovations in Drug Containment Systems and Drug Delivery Devices - including Vertiva™ platform - at booth 2K20 during the CPhI show. Visitors will have the opportunity to meet the company's experts and sales representatives to learn about the advanced offer focused on biologics, including GLP-1 obesity drugs, vaccines, diabetes, and mRNA.
